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Cerebrovascular
Complications of Infective
Endocarditis
To the Editor—We read with great in-
terest the article by Snygg-Martin et al. [1]
that was recently published in Clinical In-
fectious Diseases, which analyzed the cer-
ebrovascular complications of left-sided
infective endocarditis using MRI and neu-
rochemical brain damage markers. In that
article, the authors found an elevated in-
cidence of symptomatic and asymptom-
atic cerebrovascular complications among
patients with left-sided infective endocar-
ditis. Among the factors associated with
cerebrovascular complications, the size of
valvular vegetation was identified as a risk
factor for symptomatic and asymptomatic
complications, and only Staphylococcus
aureus infection was associated with
symptomatic complications in the micro-
biology analysis [1]. However, we feel that
some of the issues raised in this article
need to be addressed.
As noted in an article by Baddour and
Bayer [2], the overall frequency of cere-
brovascular complications in the study re-
ported by Snygg-Martin et al. [1] was very
high. However, the number of patients in-
cluded in the study was small (60 pa-
tients), only 4 cases were due to gram-
negative bacteria, and no cases were due
to Candida species or other fungi (which
are considered to be responsible for 1%–
2% of all cases of infective endocarditis)
[3]. In an extensive revision of the liter-
ature, Ellis et al. [4] found that 26% of
patients with fungal endocarditis devel-
oped symptomatic CNS involvement. In
a recently published article [5], 33 (1.2%)
of 2760 cases of infective endocarditis were
due to Candida species. In this article,
Boddley et al. [5] reported that infective
endocarditis due to Candida species was
associated with a similar incidence of cer-
ebrovascular complications, compared
with infective endocarditis due to all other
causes. In a recent comparative analysis
published by our group [6], we retro-
spectively analyzed the medical literature
on published cases of endocarditis due to
Candida parapsilosis and endocarditis due
to Candida albicans. We found that 17
(26.6%) of 64 patients with left-sided en-
docarditis due to C. parapsilosis experi-
enced symptomatic cerebrovascular com-
plications. Seven patients had intracranial
hemorrhage, and 10 patients experienced
ischemic strokes [6].
In addition, we suspect that the asso-
ciation reported by Snygg-Martin et al. [1]
of symptomatic cerebrovascular compli-
cations with S. aureus infection only, as
well as their finding of a high number of
cerebrovascular complications, might be
attributable to the small number of pa-
tients included in their study. It would be
very interesting to perform a multicenter
clinical trial to achieve a larger patient
sample that would include more cases due
to gram-negative bacteria and fungi. This
could help us to better establish the re-
lationship between the microbiological
etiology of infective endocarditis and the
risk of symptomatic and asymptomatic
cerebrovascular complications.
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Reply to Garbino
and Ambrosi
To the Editor—We thank Garbino and
Ambrosioni [1] for their interest in our
study of cerebrovascular complications
(CVC) in left-sided infective endocarditis
(IE) [2]. Our study is small, compared
with some recent studies in this area [3–
5], but the patients in our study were ep-
idemiologically well matched with patients
in the National Swedish Endocarditis Reg-
istry during the same period. Staphylococ-
cus aureus was the only microorganism
identified as a risk factor for symptomatic
CVC in our study, which is in agreement
with the findings of earlier studies [3–6].
As pointed out by Garbino and Ambro-
sioni [1], there is a need to evaluate un-
common microorganisms, such as Can-
dida species or gram-negative bacilli, as
potential risk factors for CVC. A much
